Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR1H2 | P55055 | 16/20 | 0.51 |
| ▸ | NR1H3 | Q13133 | 14/20 | 0.51 |
| ▸ | RXRA | P19793 | 10/20 | 0.51 |
| ▸ | SLC16A3 | O15427 | 1/20 | 0.45 |
| ▸ | SLC16A1 | P53985 | 1/20 | 0.45 |
| ▸ | MCTS1 | Q9ULC4 | 1/20 | 0.45 |
| ▸ | SDHB | P21912 | 1/20 | 0.42 |
| ▸ | RORC | P51449 | 1/20 | 0.39 |
| ▸ | SCD | O00767 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3571178 | 0.84 | NR1H2 (0.66) | NR1H2NR1H3RXRASLC16A3SLC16A1 | |
| SCHEMBL3574833 | 0.77 | NR1H2 (0.62) | NR1H2NR1H3RXRASLC16A3SLC16A1 | |
| SCHEMBL27733829 | 0.70 | BRD4 (0.47) | NR1H2NR1H3 | |
| SCHEMBL3584334 | 0.70 | NR1H2 (0.71) | NR1H2NR1H3RXRA | |
| SCHEMBL3577322 | 0.69 | NR1H2 (0.73) | NR1H2NR1H3RXRA | |
| SCHEMBL3578604 | 0.69 | NR1H2 (0.72) | NR1H2NR1H3RXRA | |
| SCHEMBL2257516 | 0.69 | NR1H2 (0.60) | NR1H2NR1H3RXRASLC16A3SLC16A1 | |
| SCHEMBL15988525 | 0.68 | NR1H2 (0.56) | NR1H2NR1H3RXRA | |
| SCHEMBL1482090 | 0.68 | NPC1 (0.44) | NR1H2NR1H3RXRA | |
| SCHEMBL3575818 | 0.68 | NR1H2 (0.88) | NR1H2NR1H3RXRASLC16A3SLC16A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100075964-A1 | IMIDAZOLE BASED LXR MODULATORS | EXELIXIS, INC. (US) | 2010-03-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100075964-A1 | IMIDAZOLE BASED LXR MODULATORS | NR1H2, NR1H3, NR1I2 | NR1H2 1/4885NR1H3 2/4885RXRA 17/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.